[Federal Register: March 28, 2003 (Volume 68, Number 60)]
[Notices]               
[Page 15156-15157]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28mr03-51]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Concerning Infectious JEV cDNA Clones that 
Produce Highly Attenuated Recombinant JEV, and Vaccines Thereof

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent No. 5,736,148 
entitled ``Infectious JEV cDNA Clones that Produce Highly Attenuated 
Recombinant JEV, and Vaccines Thereof,'' issued April 7, 1998. The 
United States Government, as represented by the Secretary of the Army, 
has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: cDNA clones containing the entire genome of 
Japanese encephalitis virus (JEV) were used to produce infectious, 
recombinant JEV particles with diverse virulence properties. Certain 
viruses retained the immunogenicity of JEV, but lacked the ability to 
cause encephalitis. The mutation associated with this loss of 
neurovirulence was localized to a nucleotide substitution in the codon 
encoding the 138th amino acid of the envelop protein, resulting in a 
mutation of an acidic amino acid to a basic amino acid. Attenuated 
viruses containing this mutation from the basis of a greatly improved, 
molecularly defined vaccine

[[Page 15157]]

for the prevention of Japanese encephalitis in humans.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 03-7497 Filed 3-27-03; 8:45 am]

BILLING CODE 3710-08-M